Infliximab in Crohn's disease: a look at the (not so distant) future
D Sorrentino1, G Terrosu, C Avellini
1Chair of Gastroenterology, Department of Clinical and Experimental Pathology, University of Udine School of Medicine, Udine, Italy. Sorrentino@uniud.it
Summary
Infliximab offers significant benefits for Crohn's disease (CD) but optimal timing, duration, use in strictures, and postsurgical recurrence prevention require further research and consensus.
Area of Science:
- Gastroenterology and Immunology
- Inflammatory Bowel Disease Research
Background:
- Infliximab represents a major advancement in Crohn's disease (CD) management.
- Uncertainty persists regarding optimal infliximab treatment timing, duration, and use in specific complications like strictures.
Purpose of the Study:
- To review current literature on infliximab's role in Crohn's disease.
- To specifically address efficacy and safety in patients with intestinal strictures.
- To evaluate infliximab's potential in preventing postsurgical CD recurrence.
Main Methods:
- Comprehensive literature review of recent studies on infliximab in Crohn's disease.
- Analysis of data concerning infliximab's impact on intestinal strictures.
- Evaluation of studies investigating infliximab for postsurgical recurrence prevention.
Main Results:
- Evidence suggests infliximab's efficacy in managing Crohn's disease, but optimal therapeutic strategies are debated.
- The use of infliximab in the presence of intestinal strictures warrants careful consideration regarding safety and efficacy.
- Preliminary data indicate a potential role for infliximab in reducing postsurgical recurrence of Crohn's disease.
Conclusions:
- Further research is needed to establish consensus on infliximab's optimal use in Crohn's disease algorithms.
- Careful evaluation is required for infliximab therapy in Crohn's disease patients with intestinal strictures.
- Infliximab may hold promise for preventing postsurgical recurrence in Crohn's disease, meriting further investigation.
More Related Videos
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...